New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial
An experimental injection, CBL-514, has shown promising results in reducing visceral fat in early human trials. The injection, developed by Caliway Biopharmaceuticals, triggers apoptosis in fat cells, leading to a significant reduction in dangerous belly fat surrounding organs. In a phase 2 MRI analysis, recipients had an average 12.01% reduction in visceral fat four weeks after treatment. This breakthrough could potentially open a new path to treating obesity and related health risks.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ CBL-514 injection reduces visceral fat by 12.01% in early human trials
- ✓ The injection triggers apoptosis in fat cells, leading to a significant reduction in dangerous belly fat surrounding organs
- ✓ Visceral fat in the CBL-514 group remained 10.45% below baseline at a later follow-up
What changed
Caliway Biopharmaceuticals reported phase 2 trial results for CBL-514, showing a significant reduction in visceral fat.
Live updates
-
Experimental belly fat injection reduces visceral fat by 12% in early human trials
An experimental injection, CBL-514, has shown promising results in reducing visceral fat in early human trials. The injection, developed by Caliway Biopharmaceuticals, triggers apoptosis in fat cells, leading to a significant reduction in dangerous belly fat surrounding organs. In a phase 2 MRI analysis, recipients had an average 12.01% reduction in visceral fat four weeks after treatment. This breakthrough could potentially open a new path to treating obesity and related health risks.
Why it matters
The reduction of visceral fat is crucial as it is linked to various health risks, including type 2 diabetes and heart failure. Current weight loss treatments, such as Ozempic and Wegovy, often lead to weight regain once stopped. The new injection aims to provide a more sustainable solution by targeting and destroying fat cells. Next-generation weight loss drugs focus on preserving or restoring muscle mass, which is essential for overall health.
What is confirmed
- CBL-514 injection reduces visceral fat by 12.01% in early human trials
- The injection triggers apoptosis in fat cells, leading to a significant reduction in dangerous belly fat surrounding organs
- Visceral fat in the CBL-514 group remained 10.45% below baseline at a later follow-up
Still unconfirmed
- Caliway Biopharmaceuticals' stock performance following the phase 2 results
What to watch next
- Further phase 3 trials to confirm the efficacy and safety of CBL-514
- Regulatory approvals for CBL-514
- Long-term effects of CBL-514 on patients' health and weight management
confidence 85%Sources used for this update (12)
- Fox News — New belly fat injection cuts dangerous fat surrounding organs by 12% in early human trial
- Science News — An experimental drug kills fat cells, rather than shrinking them
- Olhar Digital — next generation weight loss drugs aim to save muscle
- Science Daily — New injection makes fat cells self-destruct
- BioWorld News — New weight loss targets aim to preserve or restore muscle mass
- www.sciencedaily.com — New injection makes fat cells self-destruct | ScienceDaily
- Ad-hoc-news.de — Caliway reported phase 2 results: what it means for Caliway Biopharmaceuticals C stock
- www.postcourier.com.pg — Drum – Tidbit
- www.foxnews.com — New belly fat injection cuts dangerous fat surrounding organs ...
- theclinicaltimes.com — Experimental CBL-514 injection reduced visceral fat in a ...
- www.zetik.com — CBL-514 Cuts Visceral Fat 12% in Phase 2 Trials as 69.6% Lose ...
- www.yahoo.com — New Injection Reduces Belly Fat Without Major Weight Loss ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community